AstraZeneca Pharma India Files Annual Report for FY 2025-26

AstraZeneca Pharma India Ltd has filed its Annual Report for the financial year ended March 31, 2026, as per SEBI Listing Regulations. The report includes the Business Responsibility & Sustainability Report and the Notice of the Annual General Meeting (AGM) scheduled for August 10, 2026. The company reported a total revenue from operations of ₹22,756 million for FY 2025-26, marking a 33% year-on-year growth. This performance is attributed to their 'Growth Through Innovation' strategy, strength in Oncology and Biopharmaceuticals, and expansion in Rare Disease. The company also secured 11 regulatory approvals for medicines and indications during the year, enhancing patient access to innovation. The report details various aspects of the company's operations, financial performance, and sustainability initiatives.